Since the passage of the Biologics Price Competition and Innovation Act, the field of biosimilars has expanded and evolved. Keeping abreast of these changes helps stakeholders.
On November 7, 2023, the Federal Trade Commission announced that it is challenging more than 100 patents held by 10 branded drug companies as improperly or inaccurately listed in the.
In its May 18 ruling, the U.S. Supreme Court sided with Sanofi in Amgen v. Sanofi, 598 U.S. (2023), a dispute concerning broad functional genus claims for antibodies. The Supreme.
The U.S. Patent and Trademark Office requires that patent specifications include a written description of the technology that is sought to be patented. Not just a concern for patent.